Lidocaine Antibody (601): sc-66063

Lidocaine Antibody (601) is a mouse monoclonal IgG1 antibody that detects Lidocaine protein of non-species reactive by enzyme-linked immunosorbent assay (ELISA). Anti-Lidocaine antibody (601) is available as the non-conjugated isotype antibody. Lidocaine, a widely used amino amide-type local anesthetic and Class Ib antiarrhythmic agent, plays a crucial role in medical procedures by providing effective pain relief and stabilizing cardiac rhythms. Its mechanism of action involves the blockade of fast sodium channels in the neuronal cell membrane, which alters depolarization and prevents the transmission of action potentials, leading to its anesthetic effects. Additionally, Lidocaine′s ability to decrease automaticity in cardiac tissues by reducing the slope of phase 0 depolarization is vital for managing arrhythmias, as Lidocaine does so with minimal impact on the PR interval, QRS complex, or QT interval. However, caution is warranted, as systemic exposure to high concentrations of Lidocaine can lead to adverse effects on the central nervous system and cardiovascular system. The metabolism of Lidocaine is primarily facilitated by the liver enzyme CYP1A2, which converts approximately 90 percent of Lidocaine into active metabolites, monoethylglycinexylidide and glycinexylidide, further influencing its pharmacological profile. With a molecular weight of 234.34 g/mol and a half-life of 1.5 to 2 hours, Lidocaine remains a critical component in both anesthetic and antiarrhythmic therapies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Lidocaine Antibody (601) References:

1. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.  |  Wang, JS., et al. 1999. Pharmacol Toxicol. 85: 201-5. PMID: 10608481
2. Tedisamil and lidocaine enhance each other's antiarrhythmic activity against ischaemia-induced arrhythmias in rats.  |  Sarraf, G., et al. 2003. Br J Pharmacol. 139: 1389-98. PMID: 12922925
3. Effects of lidocaine on shock-induced vulnerability.  |  Li, L., et al. 2003. J Cardiovasc Electrophysiol. 14: S237-48. PMID: 14760929
4. Lidocaine: a foot in the door of the inner vestibule prevents ultra-slow inactivation of a voltage-gated sodium channel.  |  Sandtner, W., et al. 2004. Mol Pharmacol. 66: 648-57. PMID: 15322257
5. Prophylactic versus therapeutic administration of intravenous lidocaine for suppression of post-extubation cough following cataract surgery: a randomized double blind placebo controlled clinical trial.  |  Saghaei, M., et al. 2005. Acta Anaesthesiol Taiwan. 43: 205-9. PMID: 16450594
6. Effect of intratesticular injection of lidocaine on cardiovascular responses to castration in isoflurane-anesthetized stallions.  |  Haga, HA., et al. 2006. Am J Vet Res. 67: 403-8. PMID: 16506900
7. Mechanisms influencing the vasoactive effects of lidocaine in human skin.  |  Newton, DJ., et al. 2007. Anaesthesia. 62: 146-50. PMID: 17223807
8. Marked QRS complex abnormalities and sodium channel blockade by propoxyphene reversed with lidocaine.  |  Whitcomb, DC., et al. 1989. J Clin Invest. 84: 1629-36. PMID: 2553778
9. Effects of lidocaine and diltiazem on recovery of electrophysiologic activity during partial reperfusion following severe myocardial ischemia in canine hearts.  |  Murasato, Y., et al. 1997. J Electrocardiol. 30: 113-25. PMID: 9141606